Role reversal for anticancer agents

Same author

Two controls of cell proliferation underlie cancer relapse.

Journal of cellular physiology·2018

Same author

The S phase: Beginning, middle, and end: A perspective.

Journal of cellular biochemistry·2018

Same author

Bioregulation.

Journal of cellular physiology·2015

Same author

Suppression of cancer relapse and metastasis by inhibiting cancer stemness.

Proceedings of the National Academy of Sciences of the United States of America·2015

Same author

The pursuit of oncotargets through understanding defective cell regulation.

Oncotarget·2011

Same author

A need for basic research on fluid-based early detection biomarkers.

Cancer research·2010

Same journal

Effective treatment of human breast tumors by chimeric CCL2 and CCL8 diphtheria toxin cytotoxic peptides.

Cancer biology & therapy·2026

Same journal

NSUN2 mediates SALL2 m5C methylation to inhibit ferroptosis and promote breast cancer progression.

Cancer biology & therapy·2026

Same journal

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.

Cancer biology & therapy·2026

Same journal

ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocellular carcinoma.

Cancer biology & therapy·2026

Same journal

Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.

Cancer biology & therapy·2026

Same journal

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.

Cancer biology & therapy·2026

Related Experiment Videos

Role reversal for anticancer agents

Related Concept Videos

Two controls of cell proliferation underlie cancer relapse.

The S phase: Beginning, middle, and end: A perspective.

Bioregulation.

Suppression of cancer relapse and metastasis by inhibiting cancer stemness.

The pursuit of oncotargets through understanding defective cell regulation.

A need for basic research on fluid-based early detection biomarkers.

Effective treatment of human breast tumors by chimeric CCL2 and CCL8 diphtheria toxin cytotoxic peptides.

<i>NSUN2</i> mediates <i>SALL2</i> m5C methylation to inhibit ferroptosis and promote breast cancer progression.

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.

ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocellular carcinoma.

Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude <i>versus</i> low-altitude regions: a multi-center retrospective study.

Related Experiment Videos

Role reversal for anticancer agents

Related Concept Videos

Related Articles

Two controls of cell proliferation underlie cancer relapse.

The S phase: Beginning, middle, and end: A perspective.

Bioregulation.

Suppression of cancer relapse and metastasis by inhibiting cancer stemness.

The pursuit of oncotargets through understanding defective cell regulation.

A need for basic research on fluid-based early detection biomarkers.

Effective treatment of human breast tumors by chimeric CCL2 and CCL8 diphtheria toxin cytotoxic peptides.

<i>NSUN2</i> mediates <i>SALL2</i> m5C methylation to inhibit ferroptosis and promote breast cancer progression.

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.

ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocellular carcinoma.

Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude <i>versus</i> low-altitude regions: a multi-center retrospective study.